Most recent articles by:

Philip Cyr

Phil Cyr, is Senior Vice President of Customer Solutions for Precision Value & Health with responsibility for cell and gene therapy. Phil has over 26 years of health economics, outcomes research, health policy, and payer experience, including a strong record of conducting published research, conducting health technology appraisal within a U.S. payer, and interacting with global HTAs. Phil and his team have built the health economic evidence and value demonstration strategy for over 15 gene therapies.
- Advertisement -

The Future of Gene Therapies: Three Trends

“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...

The FDA and AAV-Based Gene Therapy Safety: What You Should Know

Science fiction author Arthur C. Clarke once commented that “Any sufficiently advanced technology is indistinguishable from magic.” Over the last couple of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm
- Advertisement -